Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1973 1
1975 1
1976 3
1977 3
1979 5
1980 7
1981 5
1982 4
1983 3
1984 7
1985 14
1986 14
1987 11
1988 13
1989 17
1990 12
1991 24
1992 20
1993 21
1994 26
1995 15
1996 15
1997 29
1998 23
1999 23
2000 28
2001 25
2002 40
2003 32
2004 29
2005 50
2006 44
2007 53
2008 39
2009 53
2010 60
2011 65
2012 81
2013 80
2014 62
2015 88
2016 100
2017 91
2018 110
2019 101
2020 116
2021 155
2022 144
2023 144
2024 96
2025 1

Text availability

Article attribute

Article type

Publication date

Search Results

1,954 results

Results by year

Filters applied: . Clear all
Page 1
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.
Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, Okamoto A, Moore KN, Efrat Ben-Baruch N, Werner TL, Cloven NG, Oaknin A, DiSilvestro PA, Morgan MA, Nam JH, Leath CA 3rd, Nicum S, Hagemann AR, Littell RD, Cella D, Baron-Hay S, Garcia-Donas J, Mizuno M, Bell-McGuinn K, Sullivan DM, Bach BA, Bhattacharya S, Ratajczak CK, Ansell PJ, Dinh MH, Aghajanian C, Bookman MA. Coleman RL, et al. Among authors: okamoto a. N Engl J Med. 2019 Dec 19;381(25):2403-2415. doi: 10.1056/NEJMoa1909707. Epub 2019 Sep 28. N Engl J Med. 2019. PMID: 31562800 Free PMC article. Clinical Trial.
Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
Robak T, Jin J, Pylypenko H, Verhoef G, Siritanaratkul N, Drach J, Raderer M, Mayer J, Pereira J, Tumyan G, Okamoto R, Nakahara S, Hu P, Appiani C, Nemat S, Cavalli F; LYM-3002 investigators. Robak T, et al. Among authors: okamoto r. Lancet Oncol. 2018 Nov;19(11):1449-1458. doi: 10.1016/S1470-2045(18)30685-5. Epub 2018 Oct 19. Lancet Oncol. 2018. PMID: 30348538 Clinical Trial.
Adult patients with confirmed stage II-IV previously untreated mantle cell lymphoma, Eastern Cooperative Oncology Group performance status score of 2 or less, who were ineligible for bone marrow transplantation, were randomly assigned (1:1) to receive six or eight 21-day cycles o …
Adult patients with confirmed stage II-IV previously untreated mantle cell lymphoma, Eastern Cooperative Oncology Group performance status s …
Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer.
Kenmotsu H, Yamamoto N, Yamanaka T, Yoshiya K, Takahashi T, Ueno T, Goto K, Daga H, Ikeda N, Sugio K, Seto T, Toyooka S, Date H, Mitsudomi T, Okamoto I, Yokoi K, Saka H, Okamoto H, Takiguchi Y, Tsuboi M. Kenmotsu H, et al. Among authors: okamoto i, okamoto h. J Clin Oncol. 2020 Jul 1;38(19):2187-2196. doi: 10.1200/JCO.19.02674. Epub 2020 May 14. J Clin Oncol. 2020. PMID: 32407216 Clinical Trial.
Patients with completely resected pathologic stage II-IIIA (TNM 7th edition) nonsquamous NSCLC were randomly assigned to receive either pemetrexed (500 mg/m(2), day 1) plus cisplatin (75 mg/m(2), day 1) or vinorelbine (25 mg/m(2), days 1 and 8) plus cisplatin …
Patients with completely resected pathologic stage II-IIIA (TNM 7th edition) nonsquamous NSCLC were randomly assigned to receive either peme …
Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702.
Okamoto H, Watanabe K, Kunikane H, Yokoyama A, Kudoh S, Asakawa T, Shibata T, Kunitoh H, Tamura T, Saijo N. Okamoto H, et al. Br J Cancer. 2007 Jul 16;97(2):162-9. doi: 10.1038/sj.bjc.6603810. Epub 2007 Jun 19. Br J Cancer. 2007. PMID: 17579629 Free PMC article. Clinical Trial.
The CE arm received carboplatin area under the curve of five intravenously (IV) on day 1 and etoposide 80 mg m(-2) IV on days 1-3. The SPE arm received cisplatin 25 mg m(-2) IV on days 1-3 and etoposide 80 mg m(-2) IV on days 1-3. ...
The CE arm received carboplatin area under the curve of five intravenously (IV) on day 1 and etoposide 80 mg m(-2) IV on days 1-3. Th …
Long-term Effects of IL-6 Receptor Blockade Therapy on Regulatory Lymphocytes and Neutrophils in Neuromyelitis Optica Spectrum Disorder.
Matsuoka T, Araki M, Lin Y, Okamoto T, Gold R, Chihara N, Sato W, Kimura A, Tachimori H, Miyamoto K, Kusunoki S, Yamamura T. Matsuoka T, et al. Among authors: okamoto t. Neurol Neuroimmunol Neuroinflamm. 2023 Oct 20;11(1):e200173. doi: 10.1212/NXI.0000000000200173. Print 2024 Jan. Neurol Neuroimmunol Neuroinflamm. 2023. PMID: 37863660 Free PMC article.
Resident Memory-like CD8+ T Cells Are Involved in Chronic Inflammatory and Neurodegenerative Diseases in the CNS.
Kimura K, Nishigori R, Hamatani M, Sawamura M, Ashida S, Fujii C, Takata M, Lin Y, Sato W, Okamoto T, Kuzuya A, Takahashi R, Yamamura T, Kondo T. Kimura K, et al. Among authors: okamoto t. Neurol Neuroimmunol Neuroinflamm. 2023 Nov 10;11(1):e200172. doi: 10.1212/NXI.0000000000200172. Print 2024 Jan. Neurol Neuroimmunol Neuroinflamm. 2023. PMID: 37949669 Free PMC article.
Tumour-derived exosomes promote the induction of monocytic myeloid-derived suppressor cells from peripheral blood mononuclear cells by delivering miR-106a-5p and miR-146a-5p in multiple myeloma.
Mizuhara K, Shimura Y, Tsukamoto T, Kanai A, Kuwahara-Ota S, Yamaguchi J, Muramatsu A, Okamoto H, Taminishi-Katsuragawa Y, Kawaji-Kanayama Y, Isa R, Mizutani S, Inaba T, Kuroda J. Mizuhara K, et al. Among authors: okamoto h. Br J Haematol. 2023 Nov;203(3):426-438. doi: 10.1111/bjh.19049. Epub 2023 Aug 16. Br J Haematol. 2023. PMID: 37584109
We previously demonstrated that myeloma cells can induce monocytic myeloid-derived suppressor cells (M-MDSCs) from healthy peripheral blood mononuclear cells (PBMCs) via the concomitant secretion of CC motif chemokine ligand 5 (CCL5) and macrophage migration inhibitory fac …
We previously demonstrated that myeloma cells can induce monocytic myeloid-derived suppressor cells (M-MDSCs) from healthy peripheral …
OPG Production Matters Where It Happened.
Tsukasaki M, Asano T, Muro R, Huynh NC, Komatsu N, Okamoto K, Nakano K, Okamura T, Nitta T, Takayanagi H. Tsukasaki M, et al. Among authors: okamoto k. Cell Rep. 2020 Sep 8;32(10):108124. doi: 10.1016/j.celrep.2020.108124. Cell Rep. 2020. PMID: 32905763 Free article.
Osteoprotegerin (OPG) is a circulating decoy receptor for RANKL, a multifunctional cytokine essential for the differentiation of tissue-specific cells in bone and immune systems such as osteoclasts, medullary thymic epithelial cells (mTECs), and intestinal microfold cells (M …
Osteoprotegerin (OPG) is a circulating decoy receptor for RANKL, a multifunctional cytokine essential for the differentiation of tissue-spec …
Osmium Tag for Post-transcriptionally Modified RNA.
Debnath TK, Okamoto A. Debnath TK, et al. Among authors: okamoto a. Chembiochem. 2018 Aug 6;19(15):1653-1656. doi: 10.1002/cbic.201800274. Epub 2018 Jun 26. Chembiochem. 2018. PMID: 29799158
5-Methylcytidine (m(5) C) and 5-methyluridine (m(5) U) are highly abundant post-transcriptionally modified nucleotides that are observed in various natural RNAs. ...This osmium tag made it possible to distinguished m(5) C and m(5) U from their isomers, …
5-Methylcytidine (m(5) C) and 5-methyluridine (m(5) U) are highly abundant post-transcriptionally modified nucleotides that ar …
Aniseikonia in various retinal disorders.
Okamoto F, Sugiura Y, Okamoto Y, Hiraoka T, Oshika T. Okamoto F, et al. Among authors: okamoto y. Graefes Arch Clin Exp Ophthalmol. 2017 Jun;255(6):1063-1071. doi: 10.1007/s00417-017-3597-x. Epub 2017 Jan 25. Graefes Arch Clin Exp Ophthalmol. 2017. PMID: 28124146
METHODS: We studied 357 patients with retinal disorders including epiretinal membrane (ERM), macular hole (MH), cystoid macular edema with branch / central retinal vein occlusion (BRVO-CME / CRVO-CME), diabetic macular edema (DME), macula-off rhegmatogenous retinal detachment ( …
METHODS: We studied 357 patients with retinal disorders including epiretinal membrane (ERM), macular hole (MH), cystoid macular edema with b …
1,954 results